Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways

Fig. 5

Expression of Src-related proteins in lung cancer cell lines treated with AC-93253 iodide. Lung cancer PC9, PC9/gef, and A549 cells were treated with AC-93253 iodide at the indicated concentrations for 72 h and then analyzed on western blots; 0 nM represents 0.1% DMSO. GAPDH was the loading control. a PI3K, JNK, Paxillin, and p130cas expression and phosphorylation levels. b MEK and ERK expression and phosphorylation levels. Protein expression was quantified by ImageJ software (NIH), and the results are shown directly below the gel graph. Each experiment was performed independently and in triplicate

Back to article page